24-24 April 2023
Qmed+
REGISTER NOW
keyboard_arrow_left See all news

Recent News

30 Jan, 2023 /
Cirtec Medical
Cirtec Medical Acquires QMD™ Precision Components Business
Cirtec Medical Corporation acquires QMD’s Precision Components business
27 Jan, 2023 /
AMADA WELD TECH
AMADA WELD TECH to Highlight Innovative Solutions for Medical Device Manufacturing at MD&M West 2023
Reliability, quality, and innovation on display in booth #2935
10 Jan, 2023 /
Qosina
Qosina introduces Irradiate to Order service for single-use bioprocess components
Qosina introduces an Irradiate to Order service for its single-use bioprocess component ...
09 Jan, 2023 /
Qosina
Qosina Announces Partnership with ILC Dover and Expanded Portfolio of Liquid Bag Chambers
Qosina announces a partnership with ILC Dover, a leader in the innovative design and pro...
05 Jan, 2023 /
Life Science Outsourcing, Inc.
Life Science Outsourcing Completes Acquisition of J-Pac Medical
Expands into biomaterials and diagnostics end-markets, broadens service offerings, and s...
Porex, Filtration Group
/ 30 Jul, 2019
keyboard_arrow_left See all news

CERTIFIED PURE POREX Media Effective in Clinical and Analytical Methodologies

A recent independent study conducted for Porex on a set of expanded offerings in the CERTIFIED PURE POREX® product lineup found that the media and filters have virtually no material additives, contaminates or heavy metals that can cause interferences in clinical, analytical and blood transfusion testing.

For the study, Porex expanded its CERTIFIED PURE POREX® program to include the award-winning FORTRESS® pipette tip filters, which provide greater protection from aerosols and aspirated liquids, as well as bonded fiber and sintered particles. Porex is the first company to rigorously test its porous polymeric materials, used in critical clinical, diagnostic and medical applications, through an extensive qualification program conducted by nationally renowned third-party laboratories. Porex will reveal the study’s findings in a white paper launched at the AACC Annual Scientific Meeting & Clinical Lab EXPO and showcase the array of CERTIFIED PURE POREX® media and filters used in diagnostics applications at Booth #3583 (Anaheim, August 4-8).

Tested by the ASTM F21012 Standard, which sanctions higher standards for better performance, CERTIFIED PURE POREX® materials have over 99.99978 percent aerosol bacterial filtration efficiency (BFE), offering a nearly perfect resistance against the material being contaminated by bacteria. The testing procedure severely challenges most filtration materials and allows a reproducible bacterial experiment. Additionally, the components underwent tests confirming ISO 10993-4 and 10993-5 biocompatibility testing regulatory compliance as well as ICP-MS, an analytical testing method with high sensitivity and, as a result, accuracy.

The study reflects Porex’s investment in rigorous testing standards and methods to provide greater assurance for diagnostic and analytical science device manufacturers and end-users. This program not only meets a critical need for significant improvement in the cleanliness of plastic consumables but is particularly crucial in overall healthcare applications, where 80 percent of all healthcare decisions affecting diagnosis or treatment involve a pathology investigation .

“It is imperative that components used during the testing process are pure and not contributing to an inaccurate diagnosis, which can lead to additional operational costs for laboratories and potential liabilities from patients who can suffer greatly from a misdiagnosis,” said Maria De Capua, vice president at Porex. “Our CERTIFIED PURE POREX components ensure that everything in the clinical and analytical supply chain—from separation filters to pipette tip filter media—will not interfere with the accuracy of testing outcomes.”

Additionally, Porex sought these extra measures to ensure the safety of components in direct contact with patients during common procedures such as those in blood transfusion medicine. Each year, there are more than 13.2 million donors in the United States,  who are screened for risk of transmissible disease. Blood samples used for diagnosis or life-saving donations drawn with ill-equipped devices can potentially harm patients and healthcare workers as well as threaten the critical blood supply.

For industry manufacturers including pharmaceutical companies undergoing expensive FDA-approved clinical trials, the third-party verification of CERTIFIED PURE POREX media and filters can grant peace of mind that virtually no test instruments will negatively impact outcomes. Preventing compromised results is the most cost-effective activity to ensure the integrity of data collection. CERTIFIED PURE POREX components proactively preserve the efficacy of results that, when jeopardized, can lead to expensive repercussions.

Porex originally initiated the Certified Pure Program in 2009 by qualifying its porous polymeric materials through analytical, clinical and life sciences testing procedures.  The CERTIFIED PURE POREX portfolio will be on display at AACC in Booth #3583.
To learn more about Porex’s CERTIFIED PURE POREX  program visit www.porex.com.

 

-----------------------------------

1  https://www.grandviewresearch.com/industry-analysis/in-vitro-diagnostics-ivd-quality-control-market

2  https://www.cdc.gov/bloodsafety/basics.html

Processing. Please wait.
Loading...